Who are CZP's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Humira® (Adalimumab), infliximab therapeutic drug monitoring, Adalimumab (ADA), SB5 (Adalimumab Biosimilar), Infliximab biosimilar, Akkermansia muciniphila + Infliximab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/czp.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

CZP — Competitive Intelligence Brief

CZP (CZP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-α inhibitor. Area: Immunology.

phase 3 TNF-α inhibitor TNF-α (Tumor Necrosis Factor-alpha) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

CZP (CZP) — Astellas Pharma Inc. CZP is a humanized monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CZP TARGET	CZP	Astellas Pharma Inc	phase 3	TNF-α inhibitor	TNF-α (Tumor Necrosis Factor-alpha)
Humira® (Adalimumab)	Humira® (Adalimumab)	Mylan Inc.	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)
infliximab therapeutic drug monitoring	infliximab therapeutic drug monitoring	Imelda GI Clinical Research Center	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)
Adalimumab (ADA)	Adalimumab (ADA)	JHSPH Center for Clinical Trials	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)
SB5 (Adalimumab Biosimilar)	SB5 (Adalimumab Biosimilar)	Samsung Bioepis Co., Ltd.	marketed	TNF-α inhibitor (monoclonal antibody biosimilar)	TNF-α (tumor necrosis factor-alpha)
Infliximab biosimilar	Infliximab biosimilar	Hanyang University Seoul Hospital	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)
Akkermansia muciniphila + Infliximab	Akkermansia muciniphila + Infliximab	Chinese Medical Association	marketed	Combination therapy: probiotic + TNF-α inhibitor	TNF-α (infliximab component); gut microbiota modulation (Akkermansia muciniphila component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-α inhibitor class)

Abbott · 1 drug in this class
Alvotech Swiss AG · 1 drug in this class
Astellas Pharma Inc · 1 drug in this class
Innovaderm Research Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CZP — Competitive Intelligence Brief. https://druglandscape.com/ci/czp. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab